Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmit ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been beaten down lately with too much selling pressure. While the stock has lost 40.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentu ...

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again.This strategic pruning can h ...

This innovative biotechnology company hopes to turn things around. Once upon a time, Ginkgo Bioworks (DNA -0.25%) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make the bull and bear arguments for Ginkgo. Bull case: A growing ...

Its vision is ambitious, but can it actually be made to work? In the last three months, Ginkgo Bioworks' (DNA -10.27%) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and in fact could well be a sign of an opportunity to buy shares at a discount -- assuming those shares can be reasonably expected to rise again in the future. Is that the case with this company, or would it be better to look for opportunities elsewhe ...

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample. The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, th ...

You don't need to buy her picks, but it's worth understanding them. Cathie Wood's commitment to buying shares of businesses working on disruptive innovations, via her ARK Innovation ETF and ARK Genomic Revolution ETF, makes her investing style very much on the riskier side of the spectrum -- especially when she invests in already risky areas like biotech. But if her theses are correct, the upside to investors could be tremendous, assuming they can tolerate what might be a very long and bumpy ride between bu ...

It needs to work within the constraints imposed by these three issues.Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA 0.70%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well.But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here ar ...

The number of cell engineering partnerships Ginkgo Bioworks has is way up, but the same can't be said about its stock price.It has been difficult to be a shareholder of Ginkgo Bioworks (DNA 0.70%) over the past year. The stock has collapsed about 72% from its peak last summer.The company's cell engineering foundry is an amazing accomplishment, but sales have stagnated. If this business only needs a little more time for the industries it serves to notice its capabilities, investors who buy now could be great ...

Ginkgo Bioworks has become a penny stock -- and that's the least of its problems,Ginkgo Bioworks (DNA -3.95%) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just $0.50. It closed Friday at $0.80, so that would be a 37.5% drop. Is Ginkgo stock a sell?Why rate Ginkgo stock a sell? Where shall ...